GEP20247655B - Crystalline salt forms of kinase inhibitor - Google Patents

Crystalline salt forms of kinase inhibitor

Info

Publication number
GEP20247655B
GEP20247655B GEAP201915849A GEAP2019015849A GEP20247655B GE P20247655 B GEP20247655 B GE P20247655B GE AP201915849 A GEAP201915849 A GE AP201915849A GE AP2019015849 A GEAP2019015849 A GE AP2019015849A GE P20247655 B GEP20247655 B GE P20247655B
Authority
GE
Georgia
Prior art keywords
kinase inhibitor
salt forms
crystalline salt
crystalline
modulating
Prior art date
Application number
GEAP201915849A
Other languages
English (en)
Inventor
Frenel Demorin
Khalid Shah
Peter Wong
Courtney S Johnson
Melanie Janelle Bevill
Stephan D Parent
Sagar Shakya
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of GEP20247655B publication Critical patent/GEP20247655B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GEAP201915849A 2019-06-03 2019-12-12 Crystalline salt forms of kinase inhibitor GEP20247655B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03

Publications (1)

Publication Number Publication Date
GEP20247655B true GEP20247655B (en) 2024-08-26

Family

ID=69160360

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201915849A GEP20247655B (en) 2019-06-03 2019-12-12 Crystalline salt forms of kinase inhibitor
GEAP202415849A GEAP202415849A (en) 2019-06-03 2019-12-12 Crystalline salt forms of kinase inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202415849A GEAP202415849A (en) 2019-06-03 2019-12-12 Crystalline salt forms of kinase inhibitor

Country Status (22)

Country Link
US (1) US20230052703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579281B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826380B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939503B (cg-RX-API-DMAC7.html)
AU (1) AU2019449809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139148A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003205A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017343A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210616A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000236A (cg-RX-API-DMAC7.html)
ES (1) ES3008963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247655B (cg-RX-API-DMAC7.html)
IL (1) IL288484A (cg-RX-API-DMAC7.html)
MA (1) MA56001A (cg-RX-API-DMAC7.html)
MX (1) MX2021014773A (cg-RX-API-DMAC7.html)
PE (1) PE20220962A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111978VA (cg-RX-API-DMAC7.html)
WO (1) WO2020247019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108034B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
GEAP202415849A (en) 2024-03-11
CO2021017343A2 (es) 2022-01-17
BR112021024300A2 (pt) 2022-01-11
CN113939503B (zh) 2024-05-07
SG11202111978VA (en) 2021-11-29
WO2020247019A1 (en) 2020-12-10
KR20220016117A (ko) 2022-02-08
CA3139148A1 (en) 2020-12-10
MX2021014773A (es) 2022-01-18
MA56001A (fr) 2022-04-06
EP3976587B1 (en) 2024-12-04
CL2021003205A1 (es) 2022-09-30
EP3976587A1 (en) 2022-04-06
JP2022535072A (ja) 2022-08-04
CR20210616A (es) 2022-03-22
PH12021553020A1 (en) 2023-08-23
KR102826380B1 (ko) 2025-06-26
ES3008963T3 (en) 2025-03-25
DOP2021000236A (es) 2022-04-18
US20230052703A1 (en) 2023-02-16
PE20220962A1 (es) 2022-06-10
CN113939503A (zh) 2022-01-14
AU2019449809A1 (en) 2021-12-16
ZA202108034B (en) 2025-02-26
AU2019449809B2 (en) 2026-02-05
IL288484A (en) 2022-01-01
EP3976587C0 (en) 2024-12-04
JP7579281B2 (ja) 2024-11-07

Similar Documents

Publication Publication Date Title
GEAP202415849A (en) Crystalline salt forms of kinase inhibitor
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
PH12022551574A1 (en) Egfr inhibitors
GEP20247596B (en) Crystalline forms and salt forms of a kinase inhibitor
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
EA201792214A1 (ru) Соединения замещенного хиназолина
EA202193015A1 (ru) Ингибиторы cdk
EA201991884A3 (ru) Ингибиторы g12c kras
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12021550857A1 (en) Compounds, compositions, and methods for modulating cdk9 activity
MX2024010863A (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cinasas dependientes de ciclina 2 (cdk2).
PH12021552513A1 (en) Pyrrole compounds
PH12022551241A1 (en) Egfr inhibitors
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
ZA202006071B (en) Antiproliferation compounds and uses thereof
PH12021552953A1 (en) Tricyclic compounds
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2020013757A (es) Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.
MX2024009648A (es) Formas cristalinas de sal de n-(4-(4-(ciclopropilmetil)piperazin-1 -carbonil)fenil)quinolin-8-sulfonamida.